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Paediatric Rheumatology has seen tremendous advances in the last decade. 
The advances in immunology and technology, coupled with legislative action 
in US and EU have led to more trials and evidence based new therapies for 
children with rheumatic diseases than any other paediatric sub-speciality. 
Importantly, this enormous progress continues to accelerate, fostered by 
major international collaborative efforts in clinical and translational research.  
Paediatric rheumatologists manage a cluster of chronic, autoimmune and/or 
auto-inflammatory conditions in children and young people. These range from 
being relatively uncommon to being extremely rare. The study of rare 
diseases has led to better understanding of pathophysiology and targeted 
treatments. These targeted treatments also find application in more common 
diseases (1).  
Recently, there has been a significant step change in recognizing the great 
value of understanding in detail the genetic, molecular and associated 
mechanistic pathways of these conditions in the very young, in whom there 
has is markedly less accumulation of significant co-morbidities and organ 
damage. This has begun an enriching process of shared knowledge between 
paediatric and adult clinical research communities that demonstrates the 
opportunity for paediatric rheumatology to impact significantly on the care and 
understanding also of adult-focussed rheumatic disorders and novel pathways 
for targeted treatments. 
In this issue, international experts from the across the field address key topics 
such as precision medicine for children with rheumatic diseases and newer 
auto-inflammatory diseases such as the interfernopathies. The advances in 
  
management of juvenile dermatomyositis, scleroderma, lupus, uveitis and 
periodic fever syndromes are also addressed. 
There continue to be many challenges in advancing knowledge in this field. 
These include ensuring that appropriate clinical trials, using methodology and 
trial design appropriate for and including the insights and perspectives of 
children and young people care carried out in paediatric rheumatology. This is 
especially important with the advent of newer molecules that are relevant to 
major clinical bedside questions, and not just in meeting regulatory 
requirements.  
As the specialty of paediatric rheumatology continues to grow and develop, 
equitable access to the very best care and new and effective treatments and 
therapies is critical across the world. 
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